Advisory Board
Azaya significantly leverages the consulting services of four highly regarded experts in the
pharmaceutical industry.
Daniel D. Von Hoff, M.D.
Daniel D. Von Hoff, M.D. is a clinical oncologist and oncology drug developer who has conducted national clinical trials with more than 200 new antineoplastic and biologic agents, more than any other investigator. Over the past 20 years, he and his colleagues have conducted early clinical investigations of most of the new agents that have been approved for cancer treatment in the United States, including gemcitabine, docetaxel, paclitaxel, topotecan, irinotecan, fludarabine, mitoxantrone, and dexrazoxone.
Dr. Von Hoff is serving a six-year term on President Bush's National Cancer Advisory Board (June 2004 - March 2010) and has served on the FDA’s Oncology Advisory Committee. He is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.
Steve Weitman, M.D., Ph.D.
Steve obtained his MD and PhD at the Medical College of Wisconsin. He is board certified in Pediatric Hematology/Oncology. Steve was most recently Chief Medical Officer and Member of the Executive Committee at ILEX Oncology where he led ILEX's successful development of clofarabine (Clolar™) and guided that product through a successful ODAC and FDA approval.
Steve is inventor on numerous patents and author of over 200 papers, abstracts and chapters in the medical literature. Steve is a consultant to various biotech and pharma companies, Associate Editor of Investigational New Drugs and reviewer for multiple journals including the American Journal of Pediatric Hematology/Oncology, Clinical Cancer Research, Cancer Research and the Journal of Clinical Oncology. In addition to his industry experience, Steve has held the positions of Assistant and Associate Professor at Southwestern Medical Center, Medical College of Wisconsin, University of Texas Health Science Center at San Antonio (with tenure) and Director of Adult and Pediatric Translational Research and holder of the Zachry Chair for Translational Research at the Institute for Drug Development in San Antonio.
